Document text
Principal Investigator: Raymond Scott McClelland
Organization: UNIVERSITY OF WASHINGTON
Fiscal Year: 2021
Award: $1,259,301
Funding agency: National Institute of Allergy and Infectious Diseases
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), causative agent of the coronavirus
disease of 2019 (COVID-19) pandemic, has infected over 126 million people worldwide and resulted in over
2.7 million deaths, including > 548,000 in the United States (March 27, 2021, WHO; www.who.int). Multiple
Phase 3 efficacy trials of SARS-CoV-2 vaccine constructs are underway or in long-term follow-up in the U.S,
and these studies have supported 3 Emergency Use Authorizations (EUAs) for COVID vaccines. The
emergence of variant strains has raised concerns about the breadth of immunity and protection achieved by
the current vaccines. WHO SAGE and CDC ACIP have identified the safety and immunogenicity of mixed
schedules as a critical and immediate research priority to inform policy on the use of mixed schedules.
Knowledge of the safety, tolerability, and immunogenicity of a boost vaccine using a heterologous platform with
the homologous or variant spike lineage administered after an EUA primary dosing is a critical piece of
information needed to inform public health decisions. The heterologous boost strategy will also provide an
opportunity to thoroughly evaluate innate, cellular, and humoral immune responses elicited from the multiple
prime boost combinations using very similar immunogens, utilizing mRNA, adenovirus- vectored, and protein-
based platforms. As new vaccines are manufactured to emerging variants, these foundational data will be key
to the evaluation of future variant and heterologous prime-boost strategies. This phase 1/2 clinical trial will
evaluate the safety and immunogenicity of different heterologous delayed doses (boosts) in those who
received an EUA vaccine (either prior to participation in this trial, or as part of this trial).
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><21+ years old><Ad vector><Adenoviral Vector><Adenovirus Vector><Adult><Adult Human><Antigens><CDC><COVID><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 vaccine><COVID-19 virus><COVID19><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 pandemic><COVID19 public health crisis><COVID19 vaccine><COVID19 virus><CV-19><CV19><Centers for Disease Control><Centers for Disease Control and Prevention><Centers for Disease Control and Prevention (U.S.)><Cessation of life><CoV disease><CoV-2><CoV2><Data><Death><Dose><Evaluation><FDA EUA><FDA Emergency Use Authorization><Food and Drug Administration EUA><Food and Drug Administration Emergency Use Authorization><Foundations><Future><Immune response><Immunity><Immunological response><Knowledge><Long-term Follow-up><Longterm Follow-up><Messenger RNA><Multi-Institutional Clinical Trial><Multi-center clinical trial><Multi-site clinical trial><Multicenter clinical trial><Multisite clinical trial><Phase><Phase 1/2 Clinical Trial><Phase I/II Clinical Trial><Policies><Proteins><Public Health><Research Priority><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Schedule><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><United States><United States Centers for Disease Control><United States Centers for Disease Control and Prevention><Universities><Vaccines><Variant><Variation><Washington><Wuhan coronavirus><adeno vector><adenovector><adulthood><base><corona virus disease><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><efficacy trial><emergency use authorization><hCoV19><host response><immune system response><immunogen><immunogenicity><immunoresponse><long-term followup><longterm followup><mRNA><nCoV2><new vaccines><next generation vaccines><novel vaccines><open label><open label study><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine for novel coronavirus>